Keywords: Vernalis, Fund raising, Business transformation, Edison Investment Research

Vernalis is "worth the wait," according to Edison

Article | 28 February 2012

Print This

The proposed £65.9 million ($104 million) equity raise (net of costs) by UK biotech firm Vernalis (LSE: VER) and multi-product in-licensing ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in